Insilico Medicine Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
04:25
Sep 08
Sep 08
Insilico anti-aging drug shows promise.
Insilico's AI-discovered drug reversed biological age by three to six years in early data, is in Phase 3, and the CEO is personally accumulating up to HK$60 million of stock because the direction looks promising.
HIGH
05:08
Aug 27
Aug 27
AI accelerates drug discovery and drives significant profitability.
Insilico Medicine is demonstrating significant profitability, with first-half revenue jumping to over $106 million driven by multiple collaboration and licensing deals. The company's AI platform drastically accelerates preclinical drug discovery, cutting years off the traditional timeline and enabling scalable, novel therapeutic breakthroughs.
HIGH
20:02
Jun 19
Jun 19
Monitor Insilico Medicine
Insilico Medicine is a pure-play AI drug discovery company based in Boston but trading on the Hong Kong stock exchange. With AI revolutionizing biotech and the FDA becoming more lenient, this company is a compelling candidate to watch while he conducts deeper research.
LOW
12:31
Jun 12
Jun 12
Insilico Medicine AI platform speeds drug discovery
Insilico's AI platform speeds preclinical drug development by at least 4x, has produced 30 developmental candidates with three in Phase 2 trials, and targets aging with a dual-purpose pipeline.
MED
About Insilico Medicine Investor Commentary
Across the available history and selected sources, Buzzberg tracks Insilico Medicine across 2 sources: 3 bullish vs 0 bearish calls from 2 authors. Historical directional balance: 75% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Latest voices: Alex Zhavoronkov, Avi Felman.